IMS CORE lab teams up with Cristal Therapeutics
Cristal Therapeutics has announced that it has secured a Horizon 2020 grant. This allows the company to further develop the CriPec Nanomedicine Platform. This will be done in collaboration with the IMS CORE lab at Maastricht University’s M4I Division of Imaging Mass Spectrometry.
Cristal Therapeutics is a phase 2 clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases. The ICARUS project will be carried out in close collaboration with the IMS CORE lab at the division of Imaging Mass Spectrometry, where CriPec® nanoparticle microlocalisation and drug release in tumours will be evaluated. Mass spectrometry imaging, technology together with Cristal Therapeutics’ expert team, will provide critical new insights to optimally design CriPec® nanomedicines with the aim of achieve superior therapeutic profiles.
The project at M4I will be led by Dr. Berta Cillero Pastor and by Prof. Ron Heeren.
For more details, read the full article on the Cristal Therapeutics website: http://cristaltherapeutics.com/cristal-therapeutics-awarded-horizon-2020-grant-to-further-develop-the-cripec-nanomedicine-platform/
Also read
-
Globalisation & Law Network seminar with Rodrigo Vallejo Garretón
On 4 July 2025, the Globalisation & Law Network had the pleasure of welcoming Dr Rodrigo Vallejo Garretón, Assistant Professor in Private Law at the University of Amsterdam.
-
Language policy in European higher education
The increased Englishization of higher education is under discussion in several European countries. What does a balanced language policy look like that does justice to both the increasingly international character of higher education and a country's language-related cultural identity? At an...
-
A pinch of LSD, taken twice daily with meals
Fast forward to 2040: if you have ADHD or another psychological disorder, the doctor may no longer prescribe Ritalin or antidepressants, but instead a low dose of magic mushrooms, truffles or LSD. Associate professor Kim Kuypers is studying the use of psychedelics as potential medicines of the...
